182 related articles for article (PubMed ID: 23295919)
1. Protein-free efavirenz concentrations in cerebrospinal fluid and blood plasma are equivalent: applying the law of mass action to predict protein-free drug concentration.
Avery LB; Sacktor N; McArthur JC; Hendrix CW
Antimicrob Agents Chemother; 2013 Mar; 57(3):1409-14. PubMed ID: 23295919
[TBL] [Abstract][Full Text] [Related]
2. Compartmentalization and antiviral effect of efavirenz metabolites in blood plasma, seminal plasma, and cerebrospinal fluid.
Avery LB; VanAusdall JL; Hendrix CW; Bumpus NN
Drug Metab Dispos; 2013 Feb; 41(2):422-9. PubMed ID: 23166317
[TBL] [Abstract][Full Text] [Related]
3. Efavirenz concentrations in CSF exceed IC50 for wild-type HIV.
Best BM; Koopmans PP; Letendre SL; Capparelli EV; Rossi SS; Clifford DB; Collier AC; Gelman BB; Mbeo G; McCutchan JA; Simpson DM; Haubrich R; Ellis R; Grant I;
J Antimicrob Chemother; 2011 Feb; 66(2):354-7. PubMed ID: 21098541
[TBL] [Abstract][Full Text] [Related]
4. The male genital tract is not a pharmacological sanctuary from efavirenz.
Avery LB; Bakshi RP; Cao YJ; Hendrix CW
Clin Pharmacol Ther; 2011 Jul; 90(1):151-6. PubMed ID: 21633344
[TBL] [Abstract][Full Text] [Related]
5. Efavirenz pharmacokinetics in cerebrospinal fluid and plasma over a 24-hour dosing interval.
Yilmaz A; Watson V; Dickinson L; Back D
Antimicrob Agents Chemother; 2012 Sep; 56(9):4583-5. PubMed ID: 22687515
[TBL] [Abstract][Full Text] [Related]
6. The Association of Intraocular Efavirenz Concentrations and HIV-1 Viral Load Among Persons With HIV.
Zhang P; Qian Y; Wang L; Suo J; Yin L; Wang Y; Zhang L; Wang Z
J Acquir Immune Defic Syndr; 2024 Jul; 96(3):299-303. PubMed ID: 38534141
[TBL] [Abstract][Full Text] [Related]
7. In Vivo Profiling and Distribution of Known and Novel Phase I and Phase II Metabolites of Efavirenz in Plasma, Urine, and Cerebrospinal Fluid.
Aouri M; Barcelo C; Ternon B; Cavassini M; Anagnostopoulos A; Yerly S; Hugues H; Vernazza P; Günthard HF; Buclin T; Telenti A; Rotger M; Decosterd LA;
Drug Metab Dispos; 2016 Jan; 44(1):151-61. PubMed ID: 26553012
[TBL] [Abstract][Full Text] [Related]
8. Efavirenz Is Predicted To Accumulate in Brain Tissue: an In Silico, In Vitro, and In Vivo Investigation.
Curley P; Rajoli RK; Moss DM; Liptrott NJ; Letendre S; Owen A; Siccardi M
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27799216
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study.
Xu L; Peng W; Song X; Li Y; Han Y; Zhu T; Fu Q; Du X; Cao W; Li T
BMC Infect Dis; 2021 Jan; 21(1):112. PubMed ID: 33485301
[TBL] [Abstract][Full Text] [Related]
10. Association between social psychological status and efavirenz and nevirapine plasma concentration among HIV patients in Kenya.
Ngayo MO; Oluka M; Bulimo WD; Okalebo FA
Sci Rep; 2021 Nov; 11(1):22071. PubMed ID: 34764325
[TBL] [Abstract][Full Text] [Related]
11. Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch.
Tiraboschi JM; Muñoz-Moreno JA; Puertas MC; Alonso-Villaverde C; Prats A; Ferrer E; Rozas N; Maso M; Ouchi D; Martinez-Picado J; Podzamczer D
HIV Med; 2015 Jul; 16(6):388-92. PubMed ID: 25721471
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and pharmacodynamic investigation of efavirenz in the semen and blood of human immunodeficiency virus type 1-infected men.
Reddy YS; Gotzkowsky SK; Eron JJ; Kim JY; Fiske WD; Fiscus SA; Petch L; Cohen MS; Kashuba AD
J Infect Dis; 2002 Nov; 186(9):1339-43. PubMed ID: 12402205
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid exposure of efavirenz and its major metabolites when dosed at 400 mg and 600 mg once daily: a randomized controlled trial.
Winston A; Amin J; Clarke A; Else L; Amara A; Owen A; Barber T; Jessen H; Avihingsanon A; Chetchotisakd P; Khoo S; Cooper DA; Emery S; Puls R; ;
Clin Infect Dis; 2015 Apr; 60(7):1026-32. PubMed ID: 25501988
[TBL] [Abstract][Full Text] [Related]
14. Impact of Efavirenz Mid-dose Plasma Concentration on Long-Term Weight Change Among Virologically Suppressed People Living With HIV.
Huang SH; Huang WC; Lin SW; Chuang YC; Sun HY; Chang SY; Kuo PH; Wu PY; Liu WC; Chiang C; Hung CC; Chang SC
J Acquir Immune Defic Syndr; 2021 Jun; 87(2):834-841. PubMed ID: 33587507
[TBL] [Abstract][Full Text] [Related]
15. Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz.
Tovar-y-Romo LB; Bumpus NN; Pomerantz D; Avery LB; Sacktor N; McArthur JC; Haughey NJ
J Pharmacol Exp Ther; 2012 Dec; 343(3):696-703. PubMed ID: 22984227
[TBL] [Abstract][Full Text] [Related]
16. Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum.
Cressey TR; Stek A; Capparelli E; Bowonwatanuwong C; Prommas S; Sirivatanapa P; Yuthavisuthi P; Neungton C; Huo Y; Smith E; Best BM; Mirochnick M;
J Acquir Immune Defic Syndr; 2012 Mar; 59(3):245-52. PubMed ID: 22083071
[TBL] [Abstract][Full Text] [Related]
17. Predicting Efavirenz Concentrations in the Brain Tissue of HIV-Infected Individuals and Exploring their Relationship to Neurocognitive Impairment.
Srinivas N; Joseph SB; Robertson K; Kincer LP; Menezes P; Adamson L; Schauer AP; Blake KH; White N; Sykes C; Luciw P; Eron JJ; Forrest A; Price RW; Spudich S; Swanstrom R; Kashuba ADM
Clin Transl Sci; 2019 May; 12(3):302-311. PubMed ID: 30675981
[TBL] [Abstract][Full Text] [Related]
18. Efavirenz and Lopinavir Levels in HIV-Infected Women and Their Nursing Infants, in Mali.
Oumar AA; Bagayoko-Maiga K; Bahachimi A; Maiga M; Cere MC; Diarra Z; Chatelut E; Sylla M; Murphy RL; Dao S; Gandia P
J Pharmacol Exp Ther; 2018 Sep; 366(3):479-484. PubMed ID: 29986950
[TBL] [Abstract][Full Text] [Related]
19. Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study.
Luetkemeyer AF; Rosenkranz SL; Lu D; Marzan F; Ive P; Hogg E; Swindells S; Benson CA; Grinsztejn B; Sanne IM; Havlir DV; Aweeka F;
Clin Infect Dis; 2013 Aug; 57(4):586-93. PubMed ID: 23592830
[TBL] [Abstract][Full Text] [Related]
20. No observable correlation between central nervous system side effects and EFV plasma concentrations in Japanese HIV type 1-infected patients treated with EFV containing HAART.
Takahashi M; Ibe S; Kudaka Y; Okumura N; Hirano A; Suzuki T; Mamiya N; Hamaguchi M; Kaneda T
AIDS Res Hum Retroviruses; 2007 Aug; 23(8):983-7. PubMed ID: 17725414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
